Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Jun 01  •  02:18PM ET
18.50
Dollar change
-0.76
Percentage change
-3.97
%
Index
-
P/E
-
EPS (ttm)
-
Insider Own
58.28%
Shs Outstand
33.43M
Perf Week
-11.25%
Market Cap
618.29M
Forward P/E
-
EPS next Y
-2.69
Insider Trans
245.41%
Shs Float
13.95M
Perf Month
-19.38%
Enterprise Value
368.90M
PEG
-
EPS next Q
-0.51
Inst Own
38.29%
Perf Quarter
-30.81%
Income
-
P/S
-
EPS this Y
87.35%
Inst Trans
25.36%
Perf Half Y
-
Sales
-
P/B
2.47
EPS next Y
-18.13%
ROA
-
Perf YTD
-29.94%
Book/sh
7.48
P/C
2.46
EPS next 5Y
43.50%
ROE
-
52W High
32.44 -42.99%
Perf Year
-
Cash/sh
7.51
P/FCF
-
EPS past 3/5Y
-69.04% -
ROIC
-
52W Low
19.02 -2.76%
Perf 3Y
-
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
- -
Gross Margin
-
Volatility
7.74% 6.91%
Perf 5Y
-
Dividend TTM
-
EV/Sales
-
EPS Y/Y TTM
-
Oper. Margin
-
ATR (14)
1.56
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
38.00
Sales Y/Y TTM
-
Profit Margin
-
RSI (14)
28.15
Dividend Gr. 3/5Y
- -
Current Ratio
38.00
EPS Q/Q
-
SMA20
-17.52%
Beta
-
Payout
-
Debt/Eq
0.01
Sales Q/Q
-
SMA50
-20.36%
Rel Volume
0.36
Prev Close
19.26
Employees
65
LT Debt/Eq
0.01
SMA200
-25.38%
Avg Volume
96.84K
Price
18.50
IPO
Feb 06, 2026
Option/Short
No / Yes
Trades
Volume
25,942
Change
-3.97%
Date Action Analyst Rating Change Price Target Change
Mar-10-26Initiated H.C. Wainwright Buy $37
Mar-03-26Initiated Stifel Buy $42
Mar-03-26Initiated Leerink Partners Outperform $42
Mar-03-26Initiated Jefferies Buy $62
Mar-03-26Initiated Citigroup Buy $42
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Co-FounderDr. Malik Y. Kahook M.D.
CEO & DirectorMr. Patrick H. Mooney
Chief Research & Development OfficerDr. Chetan Pujara Ph.D.
Co-founder & Chief Technology AdvisorMr. Glenn Sussman
Chief Financial OfficerDr. Jean-Frederic Viret Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorFeb 09 '26Buy16.003,690,00059,040,0005,966,439Feb 11 05:15 PM
Behbahani AliDirectorFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Florence Anthony A. Jr.10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
BASKETT FOREST10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
New Enterprise Associates 17, 10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Yang Rick10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Makhzoumi Mohamad10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
SANDELL SCOTT D10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Chang Carmen10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Walker Paul Edward10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Mathers Edward T10% OwnerFeb 09 '26Buy16.00937,50015,000,0006,035,038Feb 11 04:30 PM
Pardo Geoffrey BDirectorFeb 09 '26Buy16.00312,5005,000,0002,187,513Feb 11 04:09 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.00115,0001,840,000251,427Feb 11 04:07 PM
Khan Bilal ArshadDirectorFeb 09 '26Buy16.0020,000320,00025,450Feb 11 04:07 PM
Nielsen Kirk G.DirectorFeb 09 '26Buy16.00165,0002,640,0003,310,619Feb 10 06:09 PM
Vensana Capital I GP, LLC10% OwnerFeb 09 '26Buy16.00165,0002,640,0003,310,619Feb 10 06:08 PM